US Stock MarketDetailed Quotes

INTS Intensity Therapeutics

Watchlist
  • 2.926
  • +0.139+4.97%
Close Nov 29 13:00 ET
40.58MMarket Cap-2494P/E (TTM)

About Intensity Therapeutics Company

Intensity Therapeutics, Inc. operates as biotechnology company which develops novel immune-based therapeutic products for cancer treatment. Its product, INT230-6, is a formulation consisting of an amphiphilic cell penetration enhancer molecule combined with cisplatin and vinblastine. The company was founded by Lewis H. Bender in 2012 and is headquartered in Shelton, CT.

Company Profile

SymbolINTS
Company NameIntensity Therapeutics
Listing DateJun 30, 2023
Issue Price5.00
Founded2012
CEOMr. Lewis H. Bender
MarketNASDAQ
Employees17
Fiscal Year Ends12-31
Address1 Enterprise Drive,Suite 430
CityShelton
ProvinceConnecticut
CountryUnited States of America
Zip Code06484-4779
Phone1-203-221-7381
Websitehttp://www.intensitytherapeutics.com

Company Executives

  • Name
  • Position
  • Salary
  • Lewis H. Bender
  • President, Chief Executive Officer and Chairman of the Board
  • 1.24M
  • Joseph Talamo
  • Chief Financial Officer
  • 456.37K
  • John Wesolowski
  • Principal Accounting Officer and Controller
  • 527.29K
  • Dr. Emer Leahy
  • Independent Director
  • 31.75K
  • Thomas I.H. Dubin
  • Independent Director
  • --
  • Daniel J. Donovan
  • Independent Director
  • 28.75K
  • Dr. Mark A. Goldberg, M.D.
  • Independent Director
  • 26.75K

Analysis

Analyst Rating

No Data

Price Target

No Data

Heat List
US
Overall
Symbol
Latest Price
% Chg

No Data